

NCCN Pancreatic Adenocarcinoma Guidelines V.1.2011 Teleconference – Update– 08/03/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	Abstain
<p><u>PANC-8, -9, -10, and PANC-E</u></p> <p>Internal request: Consider addition of FOLFIRINOX for metastatic pancreatic cancer frontline in those with good performance status</p> <p>External submission from sanofi-aventis: Review of oxaliplatin in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRINOX) as first-line treatment of metastatic pancreatic cancer</p>	<p>Based on the referenced data, the Panel consensus was to add this regimen as first-line therapy for good performance status patients with either locally advanced or metastatic pancreatic cancer.</p>	<p>Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14:481-489 Available at: http://www.ncbi.nlm.nih.gov/pubmed/12598357..</p> <p>Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228-1236. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15718320.</p>	14	0	0
<p><u>PANC-E</u></p> <p>External submission from sanofi-aventis: Review docetaxel in combination with gemcitabine and capecitabine (GTX) as first-line treatment for metastatic pancreatic cancer.</p>	<p>Based on the referenced data, the Panel consensus was to include the combination of gemcitabine, docetaxel, and capecitabine (GTX regimen) for the treatment of patients with advanced disease and good performance status.</p>	<p>Fine RL, Fogelman DR, Schreiber SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:167-175. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17440727.</p>	14 - Voted as a category 2B	0	0
<p><u>PANC-E</u></p> <p>External submission from Abraxis BioScience, LLC: Review the data for albumin-bound paclitaxel in combination with</p>	<p>Based on the referenced data, the Panel consensus was to add albumin-bound paclitaxel in combination with gemcitabine for the treatment of patients with metastatic disease and good performance status.</p>	<p>Von Hoff DD, Ramanathan R, Borad M, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study [abstract]. J Clin Oncol 2009;27 (suppl):4525. Available at:</p>	14 – Voted as a category 2B	0	0

NCCN Pancreatic Adenocarcinoma Guidelines V.1.2011 Teleconference – Update– 08/03/10

gemcitabine for treatment of first-line advanced pancreatic cancer.		http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35160			
---	--	---	--	--	--